On July 2, the Centers for Medicare and Medicaid Services issued a proposed rule that includes a description of how the agency intends to implement the home infusion services reimbursement for home infusion clinical services associated with Medicare Part B Durable Medical Equipment infusion drugs included in section 5012 of the 21st Century Cures Act and section 50401 of the Bipartisan Budget Act of 2018. The proposed rule is open for comment until August 31, 2018.
The proposed rule's home infusion provisions are broken into two sections: "Requirements for Home Infusion Suppliers" and "Accreditation for Home Infusion Therapy Suppliers." The section regarding requirements for home infusion suppliers outlines issues paramount to home infusion companies. Specifically, this section includes the definition of an infusion drug administration calendar day and outlines the required services of a home infusion supplier. The proposed definition has two policy components which present a great concern to the industry:
The association will be working with members and stakeholders to coordinate comments on the proposed rule to meet the August 31 deadline; work with members of Congress to urge CMS to modify the proposed rule; and communicate to press outlets concerns over the policies included in this proposed rule. Every stakeholder is critical to ensuring CMS and Congress understand the professional services involved in the delivery of home infusion therapy. We encourage you to become familiar with the rule and use NHIA’s various resources to reach out to CMS and your members of Congress.
Learn about the new law and how it will affect your infusion business. Gain insight into the July 2, 2018, CMS proposed rule that jeopardizes the new law.Click here